On October 15th, Hologic Corporation (hereinafter referred to as Hologic) announced that it had reached a final acquisition agreement with Gynesonics for approximately $350 million (approximately RMB 2.5 billion).

With this acquisition, Haoluo Jie will further expand its layout in women's health products to consolidate its leading position in global women's health.

Acquiring innovative products
The Gynesonics company acquired this time is an innovative women's healthcare company headquartered in California, USA. Since its establishment in 2005, we have been committed to providing safe and effective minimally invasive treatment solutions for women with symptomatic uterine fibroids.

The Sonata system, the core product of Gynesonics, is the world's first and only FDA approved diagnostic intrauterine imaging device that can treat specific symptomatic uterine fibroids, including fibroids associated with severe menstrual bleeding, through the cervix. This is also the purpose of Haoluo Jie's huge investment in acquisition.
 The Sonata system consists of Sonata Image Guided Software (GGS), RF generator, intrauterine ultrasound probe, radiofrequency ablation (RFA) handle, and other components. The system has intelligent guidance function, which can display the graphic overlay of ablation area and thermal safety boundary on ultrasound images, helping doctors choose suitable ablation targets and deployment positions, and avoiding damage to normal tissues caused by excessive temperature.

Moreover, the Sonata system combines intrauterine ultrasound and advanced radiofrequency ablation technology:

 Non incision surgery: The Sonata system uses a cervical approach for treatment, avoiding the incision in traditional surgery. It accurately locates and ablates uterine fibroids through the vagina, completing the entire treatment process within the cervix. This surgery does not produce scars and does not require the removal or extraction of any tissue, reducing surgical trauma and recovery time. Patients usually resume normal activities within a few days after surgery, reducing hospitalization time and the risk of postoperative complications;
 Preserving the uterus: The design of the Sonata system allows patients to undergo treatment without removing the uterus, which is particularly important for women who wish to preserve their fertility;

Precision treatment: The Sonata system utilizes real-time ultrasound guidance to ensure that radiofrequency energy is accurately applied to the fibroid tissue, effectively ablating the fibroid.
At present, the Sonata system has been approved by the FDA and obtained CE certification, and can be sold in the European Union, the United Kingdom, Switzerland, and the United States, providing new treatment options for women's health worldwide.

Regarding this acquisition, Brandon Schnittker, President of the Surgical Solutions Division at Holyoke, emphasized that the Sonata system is a powerful supplement to Holyoke's existing products and will provide more treatment options for gynecological surgeons worldwide to help women suffering from severe menstrual bleeding and uterine fibroids. He also stated that this acquisition is in line with Haoluo Jie's mission to provide minimally invasive treatment options for women and to improve women's quality of life through innovative treatment methods.

Consolidate the leading position
Since its establishment in the 20th century, Haoluo Jie has been deeply involved in the fields of medical imaging and diagnosis. The company focuses on research and development, production, and sales of medical imaging, diagnostic equipment, and related software, committed to providing high-quality products and services to healthcare institutions and professionals worldwide. Haoluojie focuses on the field of women's health, and its business covers breast cancer diagnosis and treatment, cervical cancer screening, prenatal testing, osteoporosis testing, etc.:
 Breast health: including the diagnosis and treatment of breast cancer, products such as 3D mammography system;
 Medical diagnosis: covering cervical cancer screening, prenatal testing, and osteoporosis testing, etc;
 Minimally invasive surgery: providing services such as NovaSure ® Minimally invasive treatment techniques such as the Nuoshu impedance controlled endometrial resection system;
 Bone Health: Develop and sell products such as bone density detectors.

Haoluo Jie's products are concentrated in several major fields including breast health, diagnosis, bone health, medical aesthetics, and gynecological surgery. Its flagship products include Genius ™ The digital diagnostic system is the first AI digital diagnostic system for cervical cells approved by the FDA; Aptima®+ThinPrep ® Cervical Health is also a flagship product for virus detection; There are also many blockbuster products such as 3D molybdenum target technology to improve the accuracy of breast cancer detection.
Moreover, after years of development, Haoluo Jie's performance in the 2024 financial report is also very impressive. According to its Q2 quarterly financial report released in July, after excluding the sales related to COVID-19, the company's total revenue reached $1.02 billion, up 5% year on year.
In order to solidify its leading position in the global women's health field, Haoluo Jie also spent $310 million (approximately RMB 2.2 billion) to acquire the British company Endomag in July 2024. After the acquisition, Haoluo Jie plans to integrate Endomag's wireless breast intraoperative positioning technology and lymphatic tracking solutions into its surgical product portfolio, providing more choices for breast surgeons and radiologists.
Conclusion
For many years, Haoluo Jie has been committed to providing innovative treatment methods to improve the health status of women worldwide. This time, Haoluo Jie Nang has obtained the world's first and only diagnostic intrauterine imaging device, providing more treatment options for patients with uterine fibroids.

Source: https://news.yaozh.com/archive/44383.html